Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)

Market Cap	307.65B
Revenue (ttm)	155.49B
Net Income (ttm)	19.68B
Shares Out	70.05M
EPS (ttm)	270.21
PE Ratio	16.25
Forward PE	16.76
Dividend	90.00 (2.05%)
Ex-Dividend Date	Feb 26, 2026

Volume	199,400
Average Volume	139,405
Open	4,388.00
Previous Close	4,365.00
Day's Range	4,350.00 - 4,409.00
52-Week Range	3,783.00 - 4,735.00
Beta	0.15
RSI	61.57
Earnings Date	Jan 6, 2026

About TYO:4530

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as, external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to As...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1847
• Employees: 2,799
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4530

Financial Performance

In 2024, TYO:4530's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.